Anzeige
Mehr »
Dienstag, 14.10.2025 - Börsentäglich über 12.000 News
Defence-Boom 2025: Jetzt im Fokus der NATO-Partner - weitere Kursfantasie nach dieser Einladung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
168 Leser
Artikel bewerten:
(1)

DataM Intelligence 4 Market Research LLP: Medical Second Opinion Market Size to Reach USD 12.7 Billion by 2031 Amid Rising Misdiagnosis Prevention and Telemedicine Integration | By DataM Intelligence

AUSTIN, Texas and TOKYO, Oct. 14, 2025 /PRNewswire/ -- According to DataM Intelligence, "TheMedical Second Opinion Market Size reached USD 5,728 million in 2024 and is projected to rise to USD 12,701.8 million by 2031, growing at a CAGR of 14.8% during the forecast period 2024-2031." The market is expanding rapidly as patients, insurers, and healthcare providers increasingly rely on second opinions to reduce diagnostic errors, avoid unnecessary surgeries, and access global specialists.

DataM Intelligence Logo

Medical second opinions have evolved from a patient-requested reassurance to a core component of value-based healthcare. With misdiagnosis rates estimated at 11% globally and nearly 1 in 3 cancer patients seeking alternate evaluations, the demand for expert confirmation of critical diagnoses is reshaping the healthcare delivery landscape.

Digital health platforms, telemedicine, artificial intelligence (AI), and global specialist networks are enabling faster, more accurate, and more affordable access to expert medical opinions-making this market one of the fastest-growing sectors in healthcare services.

Download PDF Brochure: https://www.datamintelligence.com/download-sample/medical-second-opinion-market

Browse in-depth TOC on "Medical Second Opinion Market"

70 - Tables
66 - Figures
195 - Pages

Market Segmentation

By Disorder

In 2024, cancer dominated the medical second opinion market, accounting 33% of total revenues. Oncology cases often involve complex treatment options, major surgery decisions, and high emotional stakes-leading patients to seek validation from top-tier cancer centers and academic hospitals.

Cardiac disorders represented the second-largest share at 20%, as second opinions help assess the necessity of interventions such as bypass surgery, stent placement, or valve repair. Cardiovascular cases often involve risk-benefit evaluation, driving demand for expert consultation.

Neurological disorders accounted for nearly 15% of the market, driven by conditions such as stroke, epilepsy, Parkinson's disease, and multiple sclerosis that require highly specialized diagnostic interpretation.

Diabetes and ocular disorders together held approximately 12% share, particularly when complications arise affecting vision, kidney function, or mobility.

By Service Provider

Hospitals led the market in 2024, delivering approximately 55% of all second opinions. Academic medical centers and specialty hospitals have a strong reputation and often manage the most complex cases, making them the primary destination for in-depth evaluation.

Medical second opinion providing companies represented 25% of market share and are the fastest-growing segment, expanding at nearly 19% CAGR. These digital-first platforms connect patients with global specialists through virtual consultations, offering quick turnaround and access to top physicians without geographic limitations.

Health insurance companies contributed 17% of total revenue and are steadily increasing coverage of second opinions to avoid costly misdiagnoses and reduce unnecessary procedures. Insurers partner with hospitals and second opinion providers to integrate medical reviews into high-cost case management.

As value-based care models expand, insurers are expected to become one of the most influential drivers of second opinion adoption.

Request for Customized Sample Report as per Your Business Requirement: https://www.datamintelligence.com/customize/medical-second-opinion-market

Regional Insights: United States & Japan

United States

The U.S. accounted for approximately 40% of the global second opinion market in 2024 valued USD 2.29 billion. High healthcare costs, medical liability concerns, and availability of world-class specialists make the U.S. the most mature and dynamic market.

Key growth drivers include:

  • High rates of diagnostic errors (estimated 12 million cases annually)
  • Complex treatment pathways requiring confirmation
  • Widespread adoption of telehealth for specialist access
  • Increasing insurance coverage for second opinions
  • Rising consumer demand for choice and transparency

Recent Developments:

  • Major hospitals launched nationwide virtual second opinion programs.
  • Telemedicine platforms introduced AI-based triage to match patients with subspecialists.
  • Leading insurers expanded second opinion coverage to reduce expensive claim payouts.
  • A U.S. health system partnered with an international medical network for cross-border consultations.

With proactive investment and digital integration, the U.S. market is expected to exceed USD 5 billion by 2031.

Japan

Japan held 9% of the global market in 2024, valued at USD 515 million. Second opinion adoption is rising due to its aging population (nearly 30% over age 65), high prevalence of chronic diseases, and cultural emphasis on precision and informed decision-making.

Japanese hospitals have formalized second opinion services, often supported by government guidelines. Patients frequently seek expert confirmation for oncology, neurology, and cardiovascular treatment plans.

Recent Developments:

  • Expansion of hospital-based second opinion clinics focused on cancer and heart disease.
  • Telemedicine adoption surged in rural regions to improve specialist access.
  • Health insurance providers introduced structured second opinion programs.
  • A regional initiative established partnerships with international medical institutions for rare disease consultations.

Japan is expected to reach USD 1.2 billion by 2031, emerging as a leading market in Asia-Pacific for high-quality, specialist-driven second opinion services.

Industry Trends & Developments

Telemedicine Transformation:
Over 60% of second opinions in the U.S. are now delivered virtually, improving access and reducing costs.

AI-enhanced Diagnostics:
AI tools are being used to analyze medical records, flag risky diagnoses, and recommend alternative treatment pathways.

Cross-Border Expertise:
Patients increasingly seek opinions from international centers of excellence for rare or advanced conditions.

Insurance Integration:
Health plans offering second opinions see 18% reduction in unnecessary procedures, driving wider adoption.

Specialized Networks:
Providers are building disorder-specific expert panels (oncology, neurology, cardiac) to improve accuracy and speed.

Patient Empowerment:
Consumers are demanding transparency, multiple treatment options, and data-backed recommendations.

Buy This Exclusive Report at Just USD 4350 Only: https://www.datamintelligence.com/buy-now-page?report=medical-second-opinion-market

Competitive Landscape

Mediguide International LLC
A leader in virtual second opinions, partnering with over 50 major hospitals globally. Known for fast turnaround and clinical depth.

WorldCare Inc.
Specializes in complex and rare disease reviews, connecting patients with top academic medical centers and multidisciplinary expert panels.

Cleveland Clinic
One of the most trusted hospital brands worldwide. Offers comprehensive second opinion services for cardiac, cancer, neurological, and orthopedic conditions. Its virtual platform serves both domestic and international patients.

Teladoc Health
A pioneer in telehealth and digital consultations, Teladoc delivers tens of thousands of second opinions annually. It uses AI-based triage and has strong insurer partnerships.

AXA PPP & Helsana Group
Insurance leaders integrating second opinions into policy benefits, helping reduce claim costs and support better care decisions.

GrandOpinion, Lybrate, and Mass General Brigham are also expanding with patient-friendly platforms and specialist networks.

Leading players are investing in AI-driven case analysis, global physician networks, and insurance integration, resulting in consolidated and scalable service ecosystems.

Strategic Outlook

The Medical Second Opinion Market is at a critical growth inflection. Four forces will define its future trajectory:

  1. From "Reassurance" to "Clinical Necessity"
    Second opinions will be standard practice for high-risk, high-cost diagnoses.

  2. Telemedicine + AI = Global Access
    Virtual platforms and diagnostic AI will democratize world-class expertise.

  3. Insurance-Driven Adoption
    Insurers will mandate second opinions for surgeries, cancer treatments, and advanced therapies.

  4. Personalized, Data-Driven Medicine
    Integrated medical records and precision care will enable deeper, patient-specific recommendations.

Conclusion

The Medical Second Opinion Market, projected to grow from USD 5,728 million in 2024 to USD 12.70 billion by 2031, reflects the global shift toward accuracy, transparency, and patient-centered care. The United States is leading the way through telemedicine, AI, and insurance-backed programs, while Japan is building structured, specialist-driven second opinion models built on clinical precision and aging population needs.

As healthcare moves toward value-based outcomes, second opinions will become a standard of care, enhancing patient confidence, improving clinical decisions, and reducing unnecessary costs.

Related Report:

  1. mHealth Market Sizeto Jump from US$ 64.53 B in 2024 to US$ 195.50 B by 2033 at 13.0% CAGR.
  2. Telehealth Market Sizeto Grow from US$ 118.25 B in 2024 to US$ 478.18 B by 2033 at 17.2% CAGR.
  3. Remote Patient Monitoring Market Size: From US$ 50.2 B in 2023 to US$ 251.0 B by 2031 at 22.4% CAGR.
  4. Remote Patient Monitoring Market Size: From US$ 50.2 B in 2023 to US$ 251.0 B by 2031 at 22.4% CAGR.

About DataM Intelligence

DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.

To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

Contact:
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/medical-second-opinion-market-size-to-reach-usd-12-7-billion-by-2031-amid-rising-misdiagnosis-prevention-and-telemedicine-integration--by-datam-intelligence-302583484.html

© 2025 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.